X4 Pharmaceuticals, Inc - XFOR

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Feb 17, 2026 SCHEDULE 13G Saturn V Capital Management LP 7.36% 6,433,481 View
Feb 17, 2026 SCHEDULE 13G Xiaoying Tian 7.36% 6,433,481 View
Feb 17, 2026 SCHEDULE 13G/A Bain Capital Life Sciences Fund, L.P. 0.0% 0 View
Feb 17, 2026 SCHEDULE 13G/A Bain Capital Life Sciences Fund II, L.P. 0.07% 64,190 View
Feb 17, 2026 SCHEDULE 13G/A BCIP Life Sciences Associates, LP 0.01% 7,817 View
Feb 17, 2026 SCHEDULE 13G/A BCLS II Investco, LP 0.8% 758,598 View
Feb 17, 2026 SCHEDULE 13G/A BCLS I Investco, LP 0.09% 89,633 View
Feb 17, 2026 SCHEDULE 13G/A BCLS II Equity Opportunities, LP 7.43% 7,047,216 View
Feb 17, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND L P 2.1% 1,827,005 View
Feb 17, 2026 SCHEDULE 13G/A BVF I GP LLC 2.1% 1,827,005 View
Feb 17, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND II LP 1.5% 1,339,509 View
Feb 17, 2026 SCHEDULE 13G/A BVF II GP LLC 1.5% 1,339,509 View
Feb 17, 2026 SCHEDULE 13G/A Biotechnology Value Trading Fund OS LP 0.2% 194,535 View
Feb 17, 2026 SCHEDULE 13G/A BVF Partners OS Ltd. 0.2% 194,535 View
Feb 17, 2026 SCHEDULE 13G/A BVF GP HOLDINGS LLC 3.6% 3,166,514 View
Feb 17, 2026 SCHEDULE 13G/A BVF PARTNERS L P/IL 3.9% 3,411,993 View
Feb 17, 2026 SCHEDULE 13G/A BVF INC/IL 3.9% 3,411,993 View
Feb 17, 2026 SCHEDULE 13G/A LAMPERT MARK N 3.9% 3,411,993 View
Feb 17, 2026 SCHEDULE 13G/A Trails Edge Capital Partners, LP 5.8% 5,227,222 View
Feb 17, 2026 SCHEDULE 13G/A Trails Edge Biotechnology Master Fund, LP 5.8% 5,227,222 View
Feb 17, 2026 SCHEDULE 13G/A Ortav Yehudai 5.8% 5,227,222 View
Feb 13, 2026 SCHEDULE 13G/A Nantahala Capital Management, LLC 2.8% 2,449,468 View
Feb 13, 2026 SCHEDULE 13G/A Wilmot B. Harkey 2.8% 2,449,468 View
Feb 13, 2026 SCHEDULE 13G/A Daniel Mack 2.8% 2,449,468 View
Feb 12, 2026 SCHEDULE 13G Morgan Stanley 9.4% 8,196,489 View
Feb 12, 2026 SCHEDULE 13G Morgan Stanley Investment Management Inc. 9.4% 8,196,455 View
Feb 05, 2026 SCHEDULE 13G/A FMR LLC 9.7% 8,499,100 View
Feb 05, 2026 SCHEDULE 13G/A Abigail P. Johnson 9.7% 8,499,100 View
Jan 15, 2026 SCHEDULE 13G/A Empery Asset Management, LP 9.99% 9,043,894 View
Jan 15, 2026 SCHEDULE 13G/A Ryan M. Lane 9.99% 9,043,894 View
Nov 14, 2025 SCHEDULE 13G Nantahala Capital Management, LLC 9.99% 2,244,319 View
Nov 14, 2025 SCHEDULE 13G Wilmot B. Harkey 9.99% 2,244,319 View
Nov 14, 2025 SCHEDULE 13G Daniel Mack 9.99% 2,244,319 View
Nov 07, 2025 SCHEDULE 13G FMR LLC 14.8% 8,499,100 View
Nov 07, 2025 SCHEDULE 13G Abigail P. Johnson 14.8% 8,499,100 View
Nov 03, 2025 SCHEDULE 13G Perceptive Advisors LLC 7.6% 6,064,680 View
Nov 03, 2025 SCHEDULE 13G Joseph Edelman 7.6% 6,064,680 View
Nov 03, 2025 SCHEDULE 13G Perceptive Life Sciences Master Fund, Ltd. 7.6% 6,064,680 View
Oct 29, 2025 SCHEDULE 13D/A — — — View
Oct 21, 2025 SCHEDULE 13G Empery Asset Management, LP 9.99% 2,498,162 View
Oct 21, 2025 SCHEDULE 13G Lane Ryan M. 9.99% 2,498,162 View
Oct 21, 2025 SCHEDULE 13G Hoe Martin D. 9.99% 2,498,162 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.